Zurn Elkay is rated a Buy, driven by a leap in institutional projects planned in July of 2025, which the revenue lag structure carries into 2026-2027 results. Margins have expanded 630 bps since mid-2023, with management guiding for 35% normalized incremental margins and consistently beating EPS consensus. Zurn Elkay trades at a 46% forward P/E premium, justified by pre-committed revenue, disciplined management, robust balance sheet, and substantial share buybacks.
BAH's steady contract revenues and strong liquidity support growth, but rising expenses and competition pressure are affecting profitability.
M&T Bank shares rise after Q2 earnings top estimates as higher NII, fee income, loan growth and better credit quality offset rising expenses.
BLK tops Q2 earnings and revenue estimates as AUM climbs 22% y/y on strong net inflows, but rising expenses remain a key challenge.
Robert Half's high ROE, solid liquidity and shareholder return offer support, but fierce competition and limited long-term contracts add risks.
The headline numbers for First Horizon (FHN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DE settles its FTC right-to-repair lawsuit, opening the path to expanded repair access and continued investment in customer-focused service options.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
The headline numbers for BlackRock (BLK) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The headline numbers for Morgan Stanley (MS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
While the top- and bottom-line numbers for BNY (BNY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
While the top- and bottom-line numbers for M&T Bank (MTB) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The headline numbers for Conagra Brands (CAG) give insight into how the company performed in the quarter ended May 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Although the revenue and EPS for The PNC Financial Services Group (PNC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The Bank of New York Mellon Corporation delivered its 14th consecutive quarter of YoY revenue growth, with Q2 non-GAAP EPS up 27% and a 39.8% pre-tax margin. I maintain a Buy rating and raise my price target, citing pristine technical momentum, robust earnings growth, and positive Wall Street revisions. BNY's valuation is now fair at a 16x P/E multiple, but strong operating leverage, dividend growth, and bullish technicals support further upside.
Nebraska's 1.2 GW campus, Bloom Energy's 328 MW agreement and Finland expansion demonstrate accelerating infrastructure execution beyond market expectations. Token Factory, Eigen AI, Clarifai and AI Cloud 3.6 expand Nebius beyond GPU infrastructure into higher-margin enterprise AI software. Reflection AI's $1 billion-plus agreement validates frontier AI demand despite its existing $6.3 billion SpaceX compute commitment.
Aehr Test Systems (NASDAQ:AEHR) is scaling the Nasdaq today, last seen up 44% to trade at $100.82.
BitMine's Ethereum staking dominance signals growing institutional trust in Ethereum's staking model and its potential market impact. BitMine reports 98% of $47M quarterly revenue from Ethereum staking.
SCHW heads into Q2 earnings release with expectations for higher trading revenues, NIR and asset management fees amid strong client activity.